TSTickerStarGet alerts

Valion Bio stockholders approve reverse split authority and equity plan amendment

At a virtual special meeting on November 12, 2026, Valion Bio stockholders approved all three proposals, including authority for the board to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-12 within 12 months, without further stockholder approval. Stockholders also approved an amendment increasing the 2021 Equity Incentive Plan share reserve by 272,000 shares; the filing states that no other plan term or provision changed.

Share this story

Key takeaways

  • Stockholders approved reverse stock split authority, but the filing announces authorization rather than an executed split or a selected ratio.

  • The board has 12 months from approval to determine a ratio between not less than 1-for-2 and not greater than 1-for-12 without further stockholder approval.

  • The 2021 Equity Incentive Plan share reserve was increased by 272,000 shares, effective upon approval, with no other plan term or provision changed.

  • The reverse stock split proposal received 681,523 votes for and 444,153 against, with 9 abstentions and no broker non-votes.

  • Stockholders authorized the board to adjourn the meeting to another place or later date to solicit additional proxies if necessary or appropriate.

  • The Form 8-K reported meeting voting results and disclosed no financial results or guidance.

Key metrics

Authorized reverse stock split ratio rangeWithin 12 months from November 12, 2026
Not less than 1-for-2 and not greater than 1-for-12
2021 Equity Incentive Plan share reserve increaseEffective upon stockholder approval on November 12, 2026
272,000 shares
Common shares issued and outstanding and entitled to voteOctober 15, 2026 record date
2,155,637 shares
Special Meeting shares representedNovember 12, 2026
1,125,685 shares, approximately 52.22% of shares entitled to vote; quorum constituted
Proposal 1 reverse stock split authority votesNovember 12, 2026
681,523 for; 444,153 against; 9 abstentions; 0 broker non-votes
Proposal 2 equity plan amendment votesNovember 12, 2026
466,174 for; 131,057 against; 27 abstentions; 528,427 broker non-votes
Proposal 3 adjournment authority votesNovember 12, 2026
686,478 for; 438,311 against; 896 abstentions; 0 broker non-votes

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow VBIO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert